Search

Displaying results 1741 - 1750 of 9325 in total
  1. Drug

    Gadoxetic acid

    go.drugbank.com/drugs/DB08884
    ApprovedInvestigational

    Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug. … [A263146] Gadoxetic acid, under the form gadoxetate disodium, is marketed by Bayer HealthCare Pharmaceuticals under the brand name EOVIST and FDA approved in 2008.[A263151]

  2. Drug

    Cinnarizine

    go.drugbank.com/drugs/DB00568
    ApprovedInvestigational

    Cinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear and the vomiting … centre of the hypothalamus.

  3. Drug

    Levetiracetam

    go.drugbank.com/drugs/DB01202
    ApprovedInvestigational

    [L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics … Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders.

    Products: TAMLET-T, KELEBON-T
  4. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    [A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production. … Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying

  5. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache. … A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060]

  6. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    Seladelpar is a single enantiomer of the R-configuration. … Seladelpar works to block bile acid synthesis.[A264234]

  7. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). … of the mitogen-activated protein kinase (MAPK) pathway.

  8. Drug

    Doxazosin

    go.drugbank.com/drugs/DB00590
    ApprovedInvestigational

    [A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285] … Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension.

  9. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    [A260256] DMD tends to be more prevalent in males. … It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).

  10. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations. … [A275476] Developed to circumvent the adherence barriers and strict administration requirements of peptide-based GLP-1 therapies, its small-molecule structure enables once-daily oral dosing without food